PL2091965T3 - Szczepionki peptydowe przeciwko nowotworom z ekspresją polipeptydów MPHOSPH1 lub DEPDC1 - Google Patents

Szczepionki peptydowe przeciwko nowotworom z ekspresją polipeptydów MPHOSPH1 lub DEPDC1

Info

Publication number
PL2091965T3
PL2091965T3 PL07827901T PL07827901T PL2091965T3 PL 2091965 T3 PL2091965 T3 PL 2091965T3 PL 07827901 T PL07827901 T PL 07827901T PL 07827901 T PL07827901 T PL 07827901T PL 2091965 T3 PL2091965 T3 PL 2091965T3
Authority
PL
Poland
Prior art keywords
peptide vaccines
cancers expressing
expressing mphosph1
depdc1
polypeptides
Prior art date
Application number
PL07827901T
Other languages
English (en)
Inventor
Tomoaki Fujioka
Yusuke Nakamura
Takuya Tsunoda
Ryuji Osawa
Midori Shida
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Publication of PL2091965T3 publication Critical patent/PL2091965T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4643—Vertebrate antigens
    • A61K39/4644—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Physics & Mathematics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Plant Pathology (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
PL07827901T 2006-10-17 2007-10-16 Szczepionki peptydowe przeciwko nowotworom z ekspresją polipeptydów MPHOSPH1 lub DEPDC1 PL2091965T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85257506P 2006-10-17 2006-10-17
EP07827901.5A EP2091965B9 (en) 2006-10-17 2007-10-16 Peptide vaccines for cancers expressing mphosph1 or depdc1 polypeptides
PCT/JP2007/001122 WO2008047473A1 (en) 2006-10-17 2007-10-16 Peptide vaccines for cancers expressing mphosph1 or depdc1 polypeptides

Publications (1)

Publication Number Publication Date
PL2091965T3 true PL2091965T3 (pl) 2013-10-31

Family

ID=39313729

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07827901T PL2091965T3 (pl) 2006-10-17 2007-10-16 Szczepionki peptydowe przeciwko nowotworom z ekspresją polipeptydów MPHOSPH1 lub DEPDC1

Country Status (18)

Country Link
US (5) US8557955B2 (pl)
EP (7) EP2476697B1 (pl)
JP (2) JP5339292B2 (pl)
KR (4) KR101543622B1 (pl)
CN (5) CN102850433B (pl)
AU (1) AU2007311395B2 (pl)
BR (1) BRPI0717651A2 (pl)
CA (2) CA2915560A1 (pl)
DK (1) DK2091965T3 (pl)
ES (4) ES2545457T3 (pl)
HK (4) HK1171025A1 (pl)
IL (4) IL198186A (pl)
MX (1) MX2009004147A (pl)
PL (1) PL2091965T3 (pl)
PT (1) PT2091965E (pl)
RU (1) RU2469044C2 (pl)
SG (2) SG175566A1 (pl)
WO (1) WO2008047473A1 (pl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101175862A (zh) 2005-02-10 2008-05-07 肿瘤疗法科学股份有限公司 诊断膀胱癌的方法
JP5294271B2 (ja) * 2007-08-20 2013-09-18 オンコセラピー・サイエンス株式会社 Ｃｄｈ３ペプチド及びこれを含む薬剤
US8975086B2 (en) * 2008-08-28 2015-03-10 Oncotherapy Science, Inc. Method for treating or preventing bladder cancer using the DEPDC1 polypeptide
US20120107333A1 (en) * 2009-03-04 2012-05-03 Oncotherapy Science, Inc. Vangl1 peptides and vaccines including the same
WO2012032763A1 (en) * 2010-09-07 2012-03-15 Oncotherapy Science, Inc. Vangl1 peptides and vaccines including the same
CN103732743B (zh) * 2011-08-12 2017-03-15 肿瘤疗法科学股份有限公司 Mphosph1肽及包含它们的疫苗
JP2013058294A (ja) * 2011-09-09 2013-03-28 Toshiba Corp 磁気記録媒体及び磁気記録媒体の製造方法
EP2823824A4 (en) * 2012-03-09 2015-09-16 Oncotherapy Science Inc PHARMACEUTICAL COMPOSITION CONTAINING PEPTIDE
JP6041297B2 (ja) * 2012-08-24 2016-12-07 国立大学法人山口大学 犬リンパ腫の診断方法及び診断キット
BR112015022189A2 (pt) * 2013-03-13 2017-11-21 Katsura Misako microvesícula, método para produção e uso da mesma
MY184699A (en) 2014-04-16 2021-04-18 Juno Therapeutics Gmbh Methods, kits and apparatus for expanding a population of cells
EP3205661B1 (en) * 2014-10-07 2021-07-07 Cytlimic Inc. Hsp70-derived immunity inducing peptide
US20180200325A1 (en) * 2014-11-18 2018-07-19 Shionogi & Co., Ltd. Stabilized peptide composition
CN113388021A (zh) 2015-03-09 2021-09-14 Cytlimic公司 源于gpc3的肽、使用其的医药组合物、免疫诱导剂、及抗原呈递细胞的制造方法
ES2844049T3 (es) 2015-04-07 2021-07-21 Cytlimic Inc Adyuvante para vacunas contra el cáncer
EP3336186A4 (en) * 2015-08-12 2019-03-06 OncoTherapy Science, Inc. PEPTIDE DERIVED FROM DEPDC1 AND VACCINE CONTAINING SAME
EP3360885A4 (en) * 2015-10-08 2019-04-24 Oncotherapy Science, Inc. PEPTIDE DERIVED FROM MPHOSPH1 AND VACCINE CONTAINING SAME
MA45488A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés, kits et appareil de culture de cellules
MA45489A (fr) 2015-10-22 2018-08-29 Juno Therapeutics Gmbh Procédés de culture de cellules, kits et appareil associés
CN108474002B (zh) 2015-10-22 2023-05-23 朱诺治疗学有限公司 用于转导的方法、反应剂盒、反应剂和设备
RU2759728C2 (ru) 2016-10-11 2021-11-17 Ситлимик Инк. Лекарственное средство
WO2018092755A1 (en) * 2016-11-18 2018-05-24 Oncotherapy Science, Inc. Mphosph1 epitope peptides for th1 cells and vaccines containing the same
JP2019535270A (ja) * 2016-11-18 2019-12-12 オンコセラピー・サイエンス株式会社 Ｔｈ１細胞のためのＤＥＰＤＣ１エピトープペプチドおよびこれを含有するワクチン
CN109923121B (zh) * 2016-11-22 2022-12-23 武汉华大吉诺因生物科技有限公司 多肽及其应用
US11325959B2 (en) 2017-01-25 2022-05-10 Ose Immunotherapeutics Method for manufacturing a stable emulsion for peptide delivery
AR111625A1 (es) 2017-04-27 2019-07-31 Juno Therapeutics Gmbh Reactivos de partículas oligoméricas y métodos de uso de los mismos
CA3069047A1 (en) * 2017-07-12 2019-01-17 Nouscom Ag A universal vaccine based on shared tumor neoantigens for prevention and treatment of micro satellite instable (msi) cancers
US11338028B2 (en) 2017-12-13 2022-05-24 Inovio Pharmaceuticals, Inc. Cancer vaccines targeting LEMD1 and uses thereof
CN109932510B (zh) * 2017-12-18 2022-07-12 天津云检医学检验所有限公司 一种宫颈癌生物标志物及其检测试剂盒
CN112142824B (zh) * 2019-06-27 2022-03-11 深圳市东贵博康生化科技有限公司 具有诱导细胞毒性t淋巴细胞能力的多肽及其应用
WO2021060343A1 (ja) * 2019-09-24 2021-04-01 オンコセラピー・サイエンス株式会社 Ｕｒｌｃ１０由来ペプチドまたはｄｅｐｄｃ１由来ペプチドを認識するヒトｔ細胞が発現するｔ細胞受容体

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
WO1993003764A1 (en) 1991-08-26 1993-03-04 Cytel Corporation Hla-restricted hepatitis b virus ctl epitopes
ZA926441B (en) * 1991-08-26 1993-06-07 Cytel Corp HLA-restricted hepatitis B virus CTL epitopes.
JPH09500358A (ja) * 1993-03-11 1997-01-14 ザ ユニバーシティ オブ サザンカリフォルニア 免疫感染性クラスター・ウイルス感染のための治療的戦略
US5679647A (en) 1993-08-26 1997-10-21 The Regents Of The University Of California Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5804566A (en) 1993-08-26 1998-09-08 The Regents Of The University Of California Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
US5736524A (en) 1994-11-14 1998-04-07 Merck & Co.,. Inc. Polynucleotide tuberculosis vaccine
US5922687A (en) 1995-05-04 1999-07-13 Board Of Trustees Of The Leland Stanford Junior University Intracellular delivery of nucleic acids using pressure
US20030198642A1 (en) 1995-08-03 2003-10-23 Johannes J. Geuze Cell derived antigen presenting vesicles
US5853719A (en) 1996-04-30 1998-12-29 Duke University Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
EP0960204A4 (en) 1996-07-26 2002-01-23 Sloan Kettering Inst Cancer METHODS AND REAGENTS FOR GENETIC IMMUNIZATION
FR2766205B1 (fr) 1997-07-16 2002-08-30 Inst Nat Sante Rech Med Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
US7001999B1 (en) * 1998-04-15 2006-02-21 Ludwig Institute For Cancer Research Tumor associated nucleic acids and uses therefor
IL142216A0 (en) * 1998-09-30 2002-03-10 Corixa Corp A polypeptide containing an immunogenic portion of a native wti and pharmaceutical compositions containing the same
US20040241726A1 (en) * 1999-01-06 2004-12-02 Chondrogene Limited Method for the detection of allergies related gene transcripts in blood
US20050123938A1 (en) 1999-01-06 2005-06-09 Chondrogene Limited Method for the detection of osteoarthritis related gene transcripts in blood
US6291663B1 (en) * 1999-03-03 2001-09-18 Board Of Trustees Of The University Of Arkansas TADG-12: a novel transmembrane serine protease overexpressed in a ovarian carcinoma
US7030215B2 (en) * 1999-03-24 2006-04-18 Sangamo Biosciences, Inc. Position dependent recognition of GNN nucleotide triplets by zinc fingers
JP2003518364A (ja) * 1999-05-28 2003-06-10 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ 乳癌、胃癌および前立腺癌関連抗原ならびにそれらの使用
WO2002016598A2 (en) 2000-08-22 2002-02-28 Agensys, Inc. Nucleic acid and corresponding protein named 158p1h4 useful in the treatment and detection of bladder and other cancers
AU2001296235A1 (en) 2000-10-12 2002-04-22 Hyseq, Inc. Novel nucleic acids and polypeptides
CA2425648A1 (en) * 2000-10-19 2002-04-19 Epimmune Inc. Hla class i and ii binding peptides and their uses
US7919467B2 (en) * 2000-12-04 2011-04-05 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US7083789B2 (en) 2000-12-04 2006-08-01 Immunotope, Inc. Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
JP2005515779A (ja) * 2002-01-31 2005-06-02 ワイス アグレカナーゼ分子
AU2003222103A1 (en) 2002-03-28 2003-10-13 Idec Pharmaceuticals Corporation Novel gene targets and ligands that bind thereto for treatment and diagnosis of colon carcinomas
US20060024692A1 (en) * 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
TW200413725A (en) 2002-09-30 2004-08-01 Oncotherapy Science Inc Method for diagnosing non-small cell lung cancers
WO2005007090A2 (en) 2003-07-03 2005-01-27 President And Fellows Of Harvard College Inhibitors of the map kinase pathway
WO2006031221A1 (en) 2004-09-13 2006-03-23 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Compositions comprising t cell receptors and methods of use thereof
CN101175862A (zh) * 2005-02-10 2008-05-07 肿瘤疗法科学股份有限公司 诊断膀胱癌的方法
JP2006302684A (ja) 2005-04-21 2006-11-02 D D K Ltd カードコネクタ
EP1907581A2 (en) 2005-07-27 2008-04-09 Oncotherapy Science, Inc. Method of diagnosing small cell lung cancer
WO2007032255A1 (ja) 2005-09-13 2007-03-22 Mie University Ｔ細胞レセプター及び該レセプターをコードする核酸
US20070099251A1 (en) * 2005-10-17 2007-05-03 Institute For Systems Biology Tissue-and serum-derived glycoproteins and methods of their use
TWM336439U (en) * 2008-02-14 2008-07-11 Optivision Technology Inc Diffuser capable of light condensing
US8975086B2 (en) * 2008-08-28 2015-03-10 Oncotherapy Science, Inc. Method for treating or preventing bladder cancer using the DEPDC1 polypeptide
CN103732743B (zh) 2011-08-12 2017-03-15 肿瘤疗法科学股份有限公司 Mphosph1肽及包含它们的疫苗

Also Published As

Publication number Publication date
EP2476697B1 (en) 2015-06-17
HK1131169A1 (en) 2010-01-15
KR20090083378A (ko) 2009-08-03
SG10201502098YA (en) 2015-05-28
CA2915560A1 (en) 2008-04-24
HK1171024A1 (en) 2013-03-15
KR101493773B1 (ko) 2015-03-03
EP2091965B1 (en) 2013-05-15
KR101527473B1 (ko) 2015-06-17
EP2091965A4 (en) 2011-02-16
ES2545817T3 (es) 2015-09-16
EP2476698A2 (en) 2012-07-18
CN105693843A (zh) 2016-06-22
ES2415958T3 (es) 2013-07-29
US20120282286A1 (en) 2012-11-08
RU2009118432A (ru) 2010-11-27
EP2476697A2 (en) 2012-07-18
US20100028373A1 (en) 2010-02-04
RU2469044C2 (ru) 2012-12-10
CN102850435A (zh) 2013-01-02
EP2476698A3 (en) 2013-11-27
KR20140057681A (ko) 2014-05-13
CA2667030C (en) 2016-03-15
KR20140104057A (ko) 2014-08-27
AU2007311395A1 (en) 2008-04-24
US9017688B2 (en) 2015-04-28
CN101568550B (zh) 2012-12-26
KR101454287B1 (ko) 2014-11-04
HK1171026A1 (en) 2013-03-15
CN102850435B (zh) 2016-02-17
JP5339292B2 (ja) 2013-11-13
HK1171025A1 (en) 2013-03-15
US20130129759A1 (en) 2013-05-23
US20120288514A1 (en) 2012-11-15
IL222925A0 (en) 2012-12-31
EP2687541A1 (en) 2014-01-22
EP2687540A1 (en) 2014-01-22
US8552146B2 (en) 2013-10-08
EP2476699A3 (en) 2013-11-27
US20150231222A1 (en) 2015-08-20
KR20150015042A (ko) 2015-02-09
BRPI0717651A2 (pt) 2013-12-24
DK2091965T3 (da) 2013-08-05
EP2091965B9 (en) 2013-09-25
US9545437B2 (en) 2017-01-17
KR101543622B1 (ko) 2015-08-11
IL216713A0 (en) 2012-01-31
US8653234B2 (en) 2014-02-18
SG175566A1 (en) 2011-11-28
WO2008047473A1 (en) 2008-04-24
EP2695895A1 (en) 2014-02-12
CN102850434B (zh) 2016-04-13
CA2667030A1 (en) 2008-04-24
ES2545818T3 (es) 2015-09-16
EP2476698B1 (en) 2015-06-17
IL198186A (en) 2017-05-29
US8557955B2 (en) 2013-10-15
IL198186A0 (en) 2011-08-01
EP2476699A2 (en) 2012-07-18
IL216712A (en) 2017-07-31
JP2010506826A (ja) 2010-03-04
EP2091965A1 (en) 2009-08-26
PT2091965E (pt) 2013-06-11
AU2007311395B2 (en) 2013-02-21
CN102850434A (zh) 2013-01-02
JP2013116115A (ja) 2013-06-13
CN102850433B (zh) 2016-03-02
EP2476697A3 (en) 2013-11-27
CN101568550A (zh) 2009-10-28
IL216712A0 (en) 2012-01-31
MX2009004147A (es) 2009-06-15
ES2545457T3 (es) 2015-09-11
EP2476699B1 (en) 2015-06-17
CN102850433A (zh) 2013-01-02

Similar Documents

Publication Publication Date Title
IL222925A0 (en) Peptide vaccines for cancers expressing mphosph1 or depdc1 polypeptides
IL221062A0 (en) Stitched polypeptides
GB0721686D0 (en) Polypeptides
HK1156077A1 (en) Peptide vaccines for lung cancers expressing ttk, urlc10 or koc1 polypeptides
ZA200810738B (en) Polypeptide
GB0708376D0 (en) Novel polypeptides and uses thereof
ZA201000283B (en) Reinigung pegylierter polypeptide
GB0723712D0 (en) Peptides
EP2123666A4 (en) PEPTIDE
IL202059A0 (en) Identification of oxidatively modified peptide sequences in the proteome
GB0725201D0 (en) Peptide fusion proteins
GB0623539D0 (en) Polypeptides
GB0703945D0 (en) Peptide
IL203073A0 (en) Modified growth hormone polypeptides
GB0712302D0 (en) Chrondroitinase polypeptides
IL197675A0 (en) Peptides
EP2097439A4 (en) NEW PEPTIDE
GB0708529D0 (en) Peptide standards
GB0705251D0 (en) Peptides
GB0705115D0 (en) Peptides
EP2123751A4 (en) NEW PEPTIDE
GB0609920D0 (en) Peptides
GB0609921D0 (en) Peptides
GB0618512D0 (en) Peptides
GB0625176D0 (en) Peptides